Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
Key Financial Performance
Revenue for Q3 2025 $17.2 million, a decrease of $24.5 million year-over-year. The decline was primarily driven by reduced revenues from the CSL collaboration, reflecting lower supply agreement activity and lower amortization of the upfront payment as KOSTAIVE became a commercial product.
Revenue for 9 months ended September 30, 2025 $74.8 million, a decrease of $54.7 million year-over-year. The decline was primarily driven by reduced revenues from the CSL collaboration, reflecting lower supply agreement activity and lower amortization of the upfront payment as KOSTAIVE became a commercial product.
Total Operating Expenses for Q3 2025 $33.7 million, a decrease from $52.4 million year-over-year. The decrease was primarily due to lower manufacturing costs for the COVID, flu, and CF programs, reduced clinical trial expenses for COVID and cystic fibrosis, and lower payroll and employee benefits.
Total Operating Expenses for 9 months ended September 30, 2025 $119.8 million, a decrease from $191.8 million year-over-year. The decrease was primarily due to lower manufacturing and clinical costs related to the COVID program, lower manufacturing costs for the cystic fibrosis and flu program, and reduced payroll and benefits.
R&D Expenses for Q3 2025 $23.3 million, a decrease from $39.1 million year-over-year. The decrease was primarily driven by lower manufacturing costs for the COVID, flu, and CF programs, reduced clinical trial expenses for COVID and cystic fibrosis, and lower payroll and employee benefits.
R&D Expenses for 9 months ended September 30, 2025 $87.7 million, a decrease from $151.4 million year-over-year. The decrease was primarily driven by lower manufacturing and clinical costs related to the COVID program, lower manufacturing costs for the cystic fibrosis and flu program, and reduced payroll and benefits.
G&A Expenses for Q3 2025 $10.4 million, a decrease from $13.3 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced payroll and benefits.
G&A Expenses for 9 months ended September 30, 2025 $32.1 million, a decrease from $40.4 million year-over-year. The decrease was primarily due to reduced share-based compensation expense as well as reduced payroll and benefits.
Net Loss for Q3 2025 $13.5 million or $0.49 per diluted share, compared with a net loss of $6.9 million or $0.26 per diluted share year-over-year. The increase in net loss was not explicitly explained in the transcript.
Cash, Cash Equivalents, and Restricted Cash as of September 30, 2025 $237.3 million, compared to $293.9 million as of December 31, 2024. The decrease reflects ongoing operational expenses and cost reductions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ARCT-032 Program: This is a messenger RNA therapeutic candidate for cystic fibrosis (CF). Interim data from Phase II clinical trial showed that treatment with inhaled 10-milligram doses daily over 28 days in 6 Class I CF adults was generally safe and well tolerated. Reductions in mucus burden were observed in four of the six participants. The company plans to evaluate daily dosing over a 12-week duration in up to 20 CF participants starting in the first half of 2026.
ARCT-810 Program: This is a messenger RNA therapeutic candidate for ornithine transcarbamylase deficiency (OTC deficiency). Positive interim Phase II data has been reported. Regulatory meetings are planned for the first half of 2026 to discuss pivotal trial strategy for both pediatric and adult populations.
KOSTAIVE COVID-19 Vaccine: The Japanese partner, Meiji Seika Pharma, launched the 2-dose vial of KOSTAIVE updated for the JN.1 variant XEC in Japan. Phase III data showed robust immune response and safety. However, the BLA filing in the U.S. has been delayed indefinitely due to regulatory changes and uncertain commercial visibility.
ARCT-2304 Pandemic Influenza Vaccine: This next-gen STARR vaccine candidate for pandemic A/H5N1 influenza virus showed promising Phase I results. It induced a strong immune response after a single dose and further increased responses with a second dose. No safety or tolerability concerns were raised.
Global Expansion for CF Treatment: The company highlighted the higher prevalence of Class I CF in regions outside the U.S., including Europe, India, the Middle East, and Israel, indicating potential market expansion opportunities.
KOSTAIVE Commercialization in Asia and Europe: CSL is expected to continue supporting the commercialization of KOSTAIVE in Asia and Europe despite challenges in the U.S. market.
Cost Reductions: The company has implemented cost reductions, including lower manufacturing and clinical trial expenses for COVID, flu, and CF programs, as well as reduced payroll and employee benefits. These measures have extended the cash runway into 2028.
Financial Performance: Revenues for Q3 2025 were $17.2 million, a decrease from the previous year due to reduced revenues from the CSL collaboration. Operating expenses also decreased significantly, driven by lower R&D and G&A costs.
Focus on CF and OTC Programs: The company is prioritizing its cystic fibrosis and OTC programs, delaying other initiatives like the KOSTAIVE BLA filing in the U.S. to allocate resources effectively.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Changes Impacting KOSTAIVE: The FDA's sudden regulatory changes have indefinitely delayed the KOSTAIVE BLA filing, creating uncertainty around its commercial visibility in the U.S. This has led to reduced expenses and a focus shift to other programs.
Revenue Decline: Revenues for the third quarter and nine months ended September 30, 2025, decreased significantly compared to the same periods in 2024, primarily due to reduced revenues from the CSL collaboration and lower supply agreement activity.
Operating Expense Reductions: Operating expenses have decreased year-over-year, driven by lower manufacturing and clinical trial costs for COVID, flu, and CF programs, as well as reduced payroll and employee benefits. However, these reductions may impact the pace of program development.
Dependence on CSL Collaboration: The company relies on CSL to commercialize KOSTAIVE in Asia and Europe, which could pose risks if CSL's efforts do not meet expectations or market conditions change.
Cash Runway Extension: The delay in the Phase III cystic fibrosis clinical trial and planned cost reductions have extended the cash runway into 2028. However, this delay could slow the progress of critical programs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ARCT-032 Program for Cystic Fibrosis: The company plans to initiate a 12-week study in up to 20 CF participants in the first half of 2026 to evaluate the safety and preliminary efficacy of ARCT-032. This follows the completion of the third cohort's top-line data analysis.
ARCT-810 Program for OTC Deficiency: Regulatory meetings are planned for the first half of 2026 to discuss pivotal trial strategies for both pediatric and adult populations. The company aims to align with the FDA on the path to approval.
KOSTAIVE COVID-19 Vaccine: The company has indefinitely delayed the BLA filing for KOSTAIVE in the U.S. due to regulatory changes and uncertain commercial visibility. However, commercialization efforts will continue in Asia and Europe through CSL.
ARCT-2304 Pandemic Influenza Vaccine: The company plans to further develop ARCT-2304, a next-generation STARR vaccine candidate for pandemic A/H5N1 influenza virus, based on positive Phase I study results showing robust immune responses and no safety concerns.
Financial Guidance: Cost reductions in Q4 2025 and the delay in the Phase III cystic fibrosis trial have extended the cash runway into 2028. General and administrative expenses are expected to decrease slightly in fiscal year 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Have you been able to do PK/PD modeling for the third dose cohort, and what do you hope to gain?
A:The third cohort is being evaluated at a dose level of 15 milligrams, similar to the first two cohorts at 5 and 10 milligrams. Data collection activities are consistent with the first two cohorts. The planned 12-week safety and preliminary efficacy study will expand the population to 20 and extend the study duration from 4 to 12 weeks. Additional measures include an extra screening visit for a stable FEV1 baseline, a high-res CT scan at 12 weeks, and adding a general health questionnaire (EQ-5D-5L). PK and PD markers will remain similar to the first three cohorts.
Q:What are the optionalities for the OTC pivotal programs for pediatric and adult populations?
A:The adult population will likely involve glutamine as a biomarker, as positive data has already been collected. For children with severe disease, the focus will be on ammonia, and a single-arm study may be considered for approval. Separate regulatory discussions are expected for adults and pediatrics. The best-case scenario is gaining alignment for both populations, enabling broader approval.
Q:Do you expect mucus improvements in the 20-week study to be bronchiole or alveolar specific?
A:Mucus plugs form in smaller airways, and resolving them measures smaller airway improvements. FEV1 measures larger airways, and both are complementary. Improvements are expected over time, with the 12-week study aiming to address both lower and upper lobes. In ferrets, mucus reduction data was analyzed differently due to anatomical differences and was not directly comparable to human data.
Q:Have you updated guidance on when revenue from the KOSTAIVE program will be realized?
A:No specific guidance is provided. Meiji ordered 1.1 million doses for the fourth quarter, delivered in October-November, and is selling them in Japan. An update is expected in the year-end call in March.
Q:What metrics will drive the go/no-go decision for the 15 mg dose in the Phase II study?
A:The 15 mg cohort aims to confirm dose response and assess safety and tolerability. If well tolerated, it will likely be selected for the 12-week study. Success in the 12-week study will be defined by further mucus plug reduction and lung function improvements, potentially advancing to a Phase III trial.
Q:What is considered clinically meaningful for CT scans and mucus plugs in regulatory discussions?
A:The FDA may not yet consider CT imaging as a surrogate endpoint but may view it as supportive for a Phase III trial. The company aims to establish what is clinically meaningful, with current data showing 30-40% mucus reduction after 28 days as encouraging. Extended treatment will determine further benefits.
Q:When should we expect data from the 15 mg cohort, and what endpoints will be shown?
A:Data from the 15 mg cohort (28-day study) is expected in Q1 next year. Endpoints will include safety, tolerability, and efficacy, consistent with the first two cohorts.
Q:Will you analyze CT scans for patients who did not respond with mucus plug reduction?
A:A complete data package for all three cohorts (5, 10, and 15 mg) will be shared in a future presentation or publication, including dose response details.
Q:Will you evaluate doses higher than 15 mg?
A:No, 15 mg will be the highest dose evaluated. The decision for the 12-week study will be based on data from the 15 mg cohort.
Q:Do you need to show a correlation between mucus plug reduction and FEV1?
A:CT imaging is expected to be a supportive endpoint rather than a primary one. The company aims to collect data from the 12-week study to discuss with the FDA. FEV1 is likely to remain the primary endpoint, with CT imaging playing a supportive role.
Q:Will the extra screening visit for the 12-week study involve averaging screening visits for a more reliable baseline?
A:The current plan is to add one extra pretreatment FEV1 measurement to strengthen the baseline. Whether to average multiple measurements will be discussed with the FDA.
Q:How will you address variability in quality of life assessments for the 12-week study?
A:The study will add a general health questionnaire (EQ-5D-5L) to the existing CFQR to reduce variability and provide more comprehensive data. The approach for Phase III will depend on findings from the 12-week study.
Q:Will you include less impacted patients in the next CF cohort?
A:No, the study will not refine the list of participants based on disease severity, as success has been observed in both less advanced and more advanced cases.
Q:What is the status of the CSL collaboration and other programs?
A:CSL and Seqirus are considering a demerger, with Seqirus focusing on vaccines. COVID and flu programs are active, but no new programs have been disclosed. Updates will depend on the demerger process.
Q:What is the expected enrollment pace for the 12-week study?
A:The enrollment pace is expected to increase with additional sites in the U.S. and globally, targeting Class I and modulator nonresponders. The current cash runway guidance accounts for this expansion.
Q:What is the target age range for the OTC pediatric program?
A:The age range will be determined in regulatory discussions, with a focus on younger patients with severe disease. The goal is to proceed to pivotal trials without additional bridging studies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on KOSTAIVE commercial revenues and did not disclose details on new programs under the CSL collaboration. They also did not specify what constitutes a clinically meaningful reduction in mucus plugs or the exact correlation between CT imaging and FEV1 improvements. Additionally, they did not clarify the exact age range for the OTC pediatric program or the timeline for sharing complete data from the 15 mg cohort.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ARCT response
Arcturus Therapeutics
CF participant
COVID vaccine
CT expert
Class CF
Europe
FDA
HRCT lung
KOSTAIVE
Meiji
Phase II
Phase III
RD month
United States
activity
adult safety
afternoon Arcturus
benefit
compensation expense
cost reduction
decrease manufacturing
decrease period
influenza vaccine
lung disease
lung scan
meeting
milestone program
milligram
month decrease
mucus
payroll
people Class
physician investigator
vaccine adult
ARCT Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary indicates a mixed sentiment. Strong product development updates and international expansion are positive, but lack of specific guidance and unclear management responses in the Q&A create uncertainty. No major catalysts like partnerships or guidance changes were noted, leading to a neutral prediction for stock movement.
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call revealed strong financial performance with a significant increase in revenue and net income, driven by the mRNA platform and cost management. The increase in R&D expenses indicates ongoing investment in clinical trials, suggesting future growth potential. The operational cash flow also improved, supporting financial health. Despite some risks associated with forward-looking statements, the overall financial metrics and strategic investment in R&D provide a positive outlook for the stock price movement over the next two weeks.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary and Q&A reveal mixed signals. While there are positive developments in product pipelines and regulatory progress, management's lack of specific guidance on revenue and clinical endpoints creates uncertainty. The Q&A highlighted potential for growth but also pointed to uncertainties in clinical trial outcomes and commercial revenues. No major catalysts like new partnerships or strong financial metrics were announced, leading to a neutral sentiment overall.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Unknown8-11
The earnings call presents a mixed picture: strong pipeline developments with FDA fast track designation and cash runway extension are positives, but declining revenue and a net loss are negatives. The Q&A reveals cautious optimism about CF and OTC programs, yet management's lack of clarity on competitor impact and data release timing raises uncertainties. These factors, combined with no new partnerships or shareholder return changes, suggest a neutral stock movement prediction.
ARCT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
